2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

4:30PM-6:00PM: Abstract Number: 1945

Early Prediction of Long-Term Renal Outcomes in Lupus Nephritis Using Hazard Index Equations

4M107 ACR Abstract: SLE–Clinical II: Renal & Neuropsychiatric Disease in SLE (1941–1945)

4:30PM-6:00PM: Abstract Number: 1926

Effects of Social Networking on Chronic Disease Management in Rheumatoid Arthritis

4M104 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Beliefs & Behaviors (1923–1928)

4:30PM-6:00PM: Abstract Number: 1952

Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

4M114 ACR/ARHP Abstract: Orthopedics, Low Back Pain & Rehabilitation (1952–1957)

4:30PM-6:00PM: Abstract Number: 1954

Factors Associated with Overweight or Obesity in Athletes 5 Years after Anterior Cruciate Ligament Injury

4M114 ACR/ARHP Abstract: Orthopedics, Low Back Pain & Rehabilitation (1952–1957)

4:30PM-6:00PM: Abstract Number: 1900

FGFR3/ FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis

4M109 ACR Abstract: Systemic Sclerosis & Rel D/Os–Basic Science (1899–1904)

4:30PM-6:00PM: Abstract Number: 1925

Goal Concordance in Rheumatoid Arthritis: Beyond Pain Reduction, Is There Agreement?

4M104 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Beliefs & Behaviors (1923–1928)

4:30PM-6:00PM: Abstract Number: 1907

High Serum Adiponectin Associates with the Incidence of Rheumatoid Arthritis in Obese Subjects

4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

4:30PM-6:00PM: Abstract Number: 1930

Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission

4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

4:30PM-6:00PM: Abstract Number: 1933

Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation

4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

4:30PM-6:00PM: Abstract Number: 1909

Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women

4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

4:30PM-6:00PM: Abstract Number: 1910

Impact of Cyclic Citrullinated Peptide Autoantibody Level on Progression to Rheumatoid Arthritis Among CCP-Positive Patients without RA in a Clinical Setting

4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

4:30PM-6:00PM: Abstract Number: 1949

Implementation of a Health Diary for Patients with Fibromyalgia

4M117 ARHP Abstract: Pain, Anxiety, & Depression–ARHP I (1946–1951)

4:30PM-6:00PM: Abstract Number: 1919

Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents

4M103 ACR Abstract: Pain Mechanisms–Basic & Clinical Science (1917–1922)

4:30PM-6:00PM: Abstract Number: 1893

Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus

4M108 ACR Abstract: SLE–Etiology & Pathogenesis I (1893–1898)

4:30PM-6:00PM: Abstract Number: 1920

Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?

4M103 ACR Abstract: Pain Mechanisms–Basic & Clinical Science (1917–1922)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].